Leucid Bio

A London biotech developing next-generation CAR-T cell therapies for hard-to-treat cancers, spun out of King's College London.

About Leucid Bio

Leucid Bio develops CAR-T cell therapies, where a patient's immune cells are modified to attack cancer. It focuses on solid tumours, which existing CAR-T treatments have found hard to treat, and its lead candidate LEU011 is aimed at ovarian cancer.

It describes itself as "pioneering next-generation cell therapies for hard-to-treat cancers" (company's own words, 2021 release).

A company-data profile gives its headquarters as London, UK, and says it was spun out of King's College London, where chief scientific officer Dr John Maher leads the research. The same profile lists 11 to 50 employees, which we could not confirm.

It is a small team with a scientific leadership drawn from the university. We found no description of culture or values.

We found no information on open roles, graduate schemes, internships or apprenticeships. Small biotechs like this often hire scientists with lab experience, so look at its careers page and King's College London spin-out pages.

What they do

• {'desc': 'Engineered immune cells to find cancer cells.', 'title': 'CAR-T cell therapy'}
• {'desc': 'Aimed at cancers that standard CAR-T struggles with.', 'title': 'Solid tumour focus'}
• {'desc': 'Its in-house design approach for the cells.', 'title': 'Lateral CAR platform'}

Key facts

• Spun out of King's College London (company-data profile)
• Chief scientific officer Dr John Maher (2021 release)
• Lead candidate LEU011 is pre-clinical in a 2021 release; check current stage
• 11 to 50 employees (third-party profile)

Website: www.leucid.com